Cipla and Kemwell Biopharma announce execution of a joint venture agreement for developing, manufacturing and commercialising biosimilars Kumar Jeetendra | August 25, 2021 Mumbai, India, August 25, 2021: Cipla Limited (BSE: 500087 | NSE: CIPLA EQ, hereafter referred to as “Cipla”), a leading global pharmaceutical company and Kemwell Biopharma Private Limited, a leading biopharmaceutical Contract Development and Manufacturing Organisation (CDMO), announced execution of a joint venture agreement to develop, manufacture and commercialise biosimilars for global markets. For this …
